Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, de Groot FM, van der Lee MM, Ubink R, van den Dobbelsteen DJ, Egging DF, Dokter WH, Verheijden GF, Lemmens JM, Timmers CM, Beusker PH. Elgersma RC, et al. Among authors: lemmens jm. Mol Pharm. 2015 Jun 1;12(6):1813-35. doi: 10.1021/mp500781a. Epub 2015 Feb 18. Mol Pharm. 2015. PMID: 25635711
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
van der Lee MM, Groothuis PG, Ubink R, van der Vleuten MA, van Achterberg TA, Loosveld EM, Damming D, Jacobs DC, Rouwette M, Egging DF, van den Dobbelsteen D, Beusker PH, Goedings P, Verheijden GF, Lemmens JM, Timmers M, Dokter WH. van der Lee MM, et al. Among authors: lemmens jm. Mol Cancer Ther. 2015 Mar;14(3):692-703. doi: 10.1158/1535-7163.MCT-14-0881-T. Epub 2015 Jan 14. Mol Cancer Ther. 2015. PMID: 25589493